The US and German firms mentioned in an announcement that the doses come on high of the 300 million vaccine doses initially ordered. The EU’s govt Commission has an possibility to request an additional 100 million doses.
They mentioned the 200 million doses are anticipated to be delivered this yr, with an estimated 75 million of them within the second quarter.
The Pfizer-BioNTech vaccine was the primary of three thus far to be accepted to be used within the EU, which faces criticism for a sluggish begin to its vaccination marketing campaign in contrast with international locations comparable to Israel, Britain and the United States. The different two EU-approved vaccines are from Moderna and AstraZeneca.
“We are working relentlessly to support the further roll-out of vaccination campaigns in Europe and worldwide by expanding manufacturing capacity,” Pfizer CEO Albert Bourla mentioned.
BioNTech CEO Ugur Sahin famous that his firm will provoke manufacturing at its new plant in Marburg, Germany, this month and has strengthened its manufacturing community with additional companions.
“We are continuing to evaluate, together with governments, authorities and partners at all levels, how we might address an even higher future supply requirement for our vaccines,” he mentioned.
Wednesday’s assertion did not give monetary particulars of the deal.